Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/ritonavir versus placebo in high-risk nonhospitalized adults with COVID-19
jRCT2031210267Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing nirmatrelvir/ritonavir with placebo (2 arms). Primary endpoint: Proportion of participants with COVID-19-related hospitalization or death from any cause. Started Sep 2021; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210267.